Innoviva, Inc. → Armata Pharmaceuticals, Inc. ARMP

Item 4 in Schedule 13D is hereby supplemented as follows: On January 23, 2026, the Issuer and Innoviva Sub entered into an amendment to each of (i) the secured convertible credit and security agreement, dated as of January 10, 2023, by and among the Issuer, Innoviva Sub and the other parties thereto (as amended, the "Convertible Credit Agreement" and such amendment, the "Fifth Amendment to Convertible Credit Agreement"), which Fifth Amendment to Convertible Credit Agreement extended the maturity date of the Convertible Credit Agreement to June 1, 2027 and amended and restated certain definitions in their entirety; (ii) the credit and security agreement, dated as of July 10, 2023, by and among the Issuer, Innoviva Sub and the other parties thereto (as amended, the "July 2023 Credit Agreement" and such amendment, the "Fourth Amendment to July 2023 Credit Agreement"), which Fourth Amendment to July 2023 Credit Agreement extended the maturity date of the July 2023 Credit Agreement to June 1, 2027 and amended and restated certain definitions in their entirety; (iii) the credit and security agreement, dated as of March 4, 2024, by and among the Issuer, Innoviva Sub and the other parties thereto (as amended, the "March 2024 Credit Agreement" and such amendment, the "Second Amendment to March 2024 Credit Agreement"), which Second Amendment to March 2024 Credit Agreement extended the maturity date of the March 2024 Credit Agreement to June 1, 2027 and amended and restated certain definitions in their entirety; and (iv) the credit and security agreement, dated as of March 12, 2025, by and among the Issuer, Innoviva Sub and the other parties thereto (as amended, the "March 2025 Credit Agreement" and such amendment, the "First Amendment to March 2025 Credit Agreement"), which First Amendment to March 2025 Credit Agreement extended the maturity date of the March 2025 Credit Agreement to June 1, 2027 and amended and restated certain definitions in their entirety. On January 23, 2026, the Issuer and Innoviva Sub entered into an amendment ("Amendment No. 1 to the Warrants") to each of (i) the warrant certificate, dated as of January 26, 2021, issued by the Issuer in favor of Innoviva Sub (as amended, the "January 2021 Warrant"); (ii) the warrant certificate, dated as of March 17, 2021, issued by the Issuer in favor of Innoviva Sub (as amended, the "March 2021 Warrant"); (iii) the warrant certificate, dated as of February 9, 2022, issued by the Issuer in favor of Innoviva Sub (the "February 2022 Warrant"); and (iv) the warrant certificate, dated as of March 31, 2022, issued by the Issuer in favor of Innoviva Sub (the "March 2022 Warrant", and together with the January 2021 Warrant, the March 2021 Warrant and the February 2022 Warrant, the "Warrants", and each, a "Warrant"), which Amendment No. 1 to the Warrants extended the expiration of each Warrant to January 26, 2031. On January 23, 2026, the Issuer, Innoviva and Innoviva Sub entered into an amendment to the Second Amended and Restated Voting Agreement, dated as of February 9, 2022, by and among the Issuer, Innoviva and Innoviva Sub (as amended, the "Second A&R Voting Agreement" and such amendment, "Amendment No. 2 to the Second A&R Voting Agreement"), which Amendment No. 2 to the Second A&R Voting Agreement amended and restated the definition of "Expiration Date" to mean the earlier of (i) January 26, 2031 or (ii) approval by the U.S. Food and Drug Administration of any product candidates of the Issuer for marketing and commercial distribution. On the date of this Amendment No. 14, the Reporting Persons collectively own 25,076,769 shares of Common Stock of the Issuer, warrants to acquire an additional 10,653,847 shares of Common Stock of the Issuer, and the right to acquire an additional 19,736,843 shares of Common Stock of the Issuer upon conversion of the convertible loan (excluding any accrued interest).